<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274403</url>
  </required_header>
  <id_info>
    <org_study_id>MM03</org_study_id>
    <nct_id>NCT01274403</nct_id>
  </id_info>
  <brief_title>A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Studio Linfomi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare efficacy and toxicity of melphalan and prednisone versus
      meplhalan, prednisone and Thalidomide in elderly patients with multiple myeloma or patients
      with multiple myeloma but not eligible for high dose treatment with stem cells support.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy</measure>
    <time_frame>from 8 to 12 months</time_frame>
    <description>To compare the percentage of response in term of complete response, partial response, minimal and stable disease in the 2 arms o treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the toxicity</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>To evaluate the toxicity in the 2 arms of treatment utilized the common terminology criteria for adverse events (CTCAE) version 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Overall Survival (OS) in the 2 arms of treatment</measure>
    <time_frame>From 1 to 60 months</time_frame>
    <description>OS was defined as the time from the date of first treatment after diagnosis of multiple myeloma to the date of last follow up examination or the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Duration of Remission (DR) in the 2 arms of treatment</measure>
    <time_frame>From 8 to 60 months</time_frame>
    <description>DR was defined from the date of Complete Remission, Partial Remission, Minimal response after the completion of MPT or MP cycles to the date of disease progression or the date of last follow up examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Melphalan, prednisone plus Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan and Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan, Prednisone and Thalidomide</intervention_name>
    <arm_group_label>Melphalan, prednisone plus Thalidomide</arm_group_label>
    <arm_group_label>Melphalan and Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed of multiple myeloma.

          -  Age &gt; 65 years

          -  ECOG &lt;= 3

          -  Written informed consent given at the time of randomization

          -  Patients with age &lt;= 65 but not eligible for high dose treatment with stem cells
             support

        Exclusion Criteria:

          -  ECOG &gt; 3

          -  current neoplasm..

          -  contraindications to use thalidomide

          -  peripheral neurophaty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gruppo Italiano Studio Linfoma</name>
      <address>
        <city>Modena</city>
        <zip>41120</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gruppo Italiano Studio Linfoma</name_title>
    <organization>GISL</organization>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Elderly patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

